2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study

BACKGROUND: Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic patients with newly diagnosed AML or MDS. ISAV is an extended spectrum triazole with superior tolerability, reliability of absorption, fewer drug–drug interactions, lack of QT(c) prolongation or need for therapeutic d...

詳細記述

保存先:
書誌詳細
出版年:Open Forum Infect Dis
主要な著者: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Kadia, Tapan M, Borthakur, Gautam, Ravandi-Kashani, Farhad, Masarova, Lucia, Konopleva, Marina, Estrov, Zeev, Takahashi, Koichi, Yilmaz, Musa, Rausch, Caitlin R, Marx, Kayleigh, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811325/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1801
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料